{"disease":{"id":"extensive-stage-small-cell-lung-cancer-es-sclc","name":"extensive stage small cell lung cancer es sclc"},"drugs":{"marketed":[{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."},{"drug_id":"tarlatamab","indication_name":"extensive stage small cell lung cancer (ES-SCLC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Imdelltra (Amg757)","generic_name":"TARLATAMAB","company_name":"Amgen Inc","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":55,"revenue":null,"mechanism":"Imdeldtra works by binding to a specific target on cancer cells, which helps to slow or stop the growth of the cancer."}],"pipeline":[],"offLabel":[],"totalMarketed":2,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06530797","title":"A Multicenter Real-World Cohort Study of Adebrelimab Injection in the Treatment of Extensive-Stage Small Cell Lung Cancer","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT07472517","title":"DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemotherapy","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":670,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06748495","title":"Real-world First-line Serplulimab-based Immunochemotherapy for Extensive-stage Small Cell Lung Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Hunan Cancer Hospital","has_results":false},{"nct_id":"NCT06663098","title":"Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":142,"lead_sponsor_name":"Gruppo Oncologico Italiano di Ricerca Clinica","has_results":false},{"nct_id":"NCT06961201","title":"Nano-crystalline Megestrol Acetate Combined With Standard Treatment Versus Standard Treatment for First-line Extensive-stage Small Cell Lung Cancer in the Cachexia Phase","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":94,"lead_sponsor_name":"Changchun GeneScience Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT06838208","title":"Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Anhui Provincial Cancer Hospital","has_results":false},{"nct_id":"NCT07063407","title":"Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Shanghai Hansoh Biomedical Co., Ltd","has_results":false},{"nct_id":"NCT06909383","title":"Nanocrystalline Megestrol Acetate for the Treatment of Anorexia-Cachexia Syndrome in Extensive-Stage Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm Phase II Clinical Study","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":41,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT07061535","title":"Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT07070011","title":"Small Extracellular Vesicle miRNAs as Predictive Biomarkers for Immunochemotherapy Efficacy in Extensive-stage Small Cell Lung Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"Shanghai Chest Hospital of Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT07425795","title":"Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"Chongqing University Cancer Hospital","has_results":false},{"nct_id":"NCT07339059","title":"Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":35,"lead_sponsor_name":"Bindu R Potugari","has_results":false},{"nct_id":"NCT07501169","title":"Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":33,"lead_sponsor_name":"Sichuan University","has_results":false},{"nct_id":"NCT06853678","title":"Second-line Immunotherapy for ES-SCLC","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false},{"nct_id":"NCT06758700","title":"Post-line Treatment With Teniposide for c-Myc-driven Extensive-stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Shanghai Pulmonary Hospital, Shanghai, China","has_results":false},{"nct_id":"NCT06052423","title":"ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Hansoh BioMedical R&D Company","has_results":false}],"total":16},"guidelines":[],"source":"Drug Landscape verified database"}